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Abstract
Cervical cancer is a disease that is caused by persistent human papillo-
mavirus (HPV) infection. The fate of this sexually transmitted infection is 
determined by long-term host-viral and host-environmental interactions. 
Given that the majority population of Han Chinese have a similarity in 
genetic makeup, and cultural and social systems, it is not surprising to see a 
common spectrum of type- or variant-specific HPV prevalence and risk for 
cervical cancer in Taiwan, Hong Kong and Singapore. These populations 
also share similar behavioral and environmental exposure risks, as well 
as genetic susceptibility to cervical cancer. In this post-genomic era, when 
the code, control and function of the human genome are being quickly 
unveiled, new genetic and epigenetic biomarkers for cervical cancer are 
emerging systemically and in an overwhelming way. This review covers 
the conventional epidemiological risks of HPV infection and the develop-
ment of cervical cancer, as well as the emerging new molecular biomark-
ers, in a focused population of Chinese subjects in Southeast Asia and 
Southern China. [Tzu Chi Med J 2008;20(2):91–100]
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1. Ancestors and origin of Chinese 
populations in Taiwan and 
Southeast Asia
The Han people, sharing the same culture and lan-
guage, are by far the largest ethnic group in the world. 
Aside from the more than one billion people living in 
mainland China, over 30 million Han Chinese live in 
Taiwan, Hong Kong and Singapore, representing 98%, 
95% and 77% of their populations, respectively. Most 
of them are immigrants from the southeast coast of 
China. Starting from the 5th century, after the fall of 
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the Han Dynasty, there were three waves of large-scale 
migration of people from Northern China to Southern 
China, and to the southeast coast, including Hong 
Kong (Fig. 1). The massive movements resulted in the 
demographic expansion of Han people and their cul-
ture. Over one millennium, gene flow between the Han 
population and the native populations, most of them 
originating from Southeast Asia [1], shaped the genetic 
profile of the population in Hong Kong, and those 
who had immigrated to Taiwan, Singapore and other 
countries in Southeast Asia over the past 400 years. 
Observations of haplotypes in mitochondria DNA 
and Y chromosomes are in line with these historical 
accounts [2].
Although sharing common ancestry, populations in 
Taiwan, Hong Kong and Singapore differ to some ex-
tent from that in China, mainly because of gene flow 
from the native populations, such as the aborigines 
in Taiwan, and Thais, Malays and Indians in Singapore. 
A recent large-scale immigration of Han Chinese from 
all over mainland China to Taiwan around 1949 also 
contributed significantly to the population constituents 
in Taiwan. Moreover, early colonization by the English, 
Spanish and Dutch from the 17th to 19th centuries, and 
the fast globalization of these three areas has also 
added characteristics to these Chinese immigrants.
The cultural and genetic makeup of Chinese immi-
grants in Taiwan, Hong Kong and Singapore very much 
determine the risk of cervical cancer development, 
by affecting behavior and environmental exposure re-
lating to carcinogenesis, as well as genetic suscepti-
bility to carcinogenesis. Known determinants of cervical
carcinogenesis, including infection and persistence 
of human papillomavirus (HPV), sexual behavior, preg-
nancy and type of birth, exposure to smoking and in-
fectious agents, and genetic and epigenetic changes 
of genes in Chinese immigrants, will be the focus of 
this review.
2. HPV coevolves with its human host
Infection by HPV, the first necessary etiological factor 
found in human cancers, has been found to cause a 
high risk of cervical cancer development. HPV co-
evolved with its human host long before the origin of 
Homo sapiens some 500 million years ago. In asso-
ciation with the migration of early human ancestors, 
the variants defined by small-scale DNA sequence var-
iations of the locus control region (LCR) of specific 
HPV are unique to each ethnic group. For instance, 
specific haplotypes of HPV 16 and 18 were identified 
in the Chinese population living in Singapore [3–5]. 
Sequence analysis of HPV 31 and 52 also showed co-
localization of HPV variants, collected from Taiwan 
and Hong Kong, in the evolutional tree [6]. A common 
pattern of HPV type and variant distribution, and ge-
netic traits related to HPV infection and carcinogenesis 
are, therefore, expected in these three regions. Within 
this Chinese immigrant pattern of HPV distribution 
is the more prevalent HPV 52 and HPV 58 infections 
[7], and the sharing of Asian variants of HPV 16 and 
18 [3,4], which have different biological and clinical 
significance in cervical carcinogenesis.
A showcase of the ethnic-specific distribution of 
HPV in Chinese populations is shown in Fig. 2: the dis-
tribution of HPV genotypes in the general population 
in Taiwan differs greatly from that in Shenyang (a major 
city in Northern China) and less so from that in Shen-
zang (a major city in Southern China). Of note is the 
difference in the prevalence of HPV 16, which is very 
dominant in north China [8,9], less dominant in south 
China [10], and is similar to HPV 52 and 58 in Taiwan 
[11]. A similar ethnic-specific distribution of HPV types 
was also noted in cervical cancer from different areas. 
As shown in Fig. 3 [12–15], HPV 16 was found in 80% 
of cervical cancers in China [12] but was found in only 
50% of cervical cancers in Taiwan and south China 
[13], and other Asian countries [14,16]. In areas with 
Chinese immigrants, such as Taiwan [17,18] and Hong 
Kong [19], and in Southern China [20,21], HPV 58 is 
the second or the third most common HPV type found 
in cervical cancer but the same HPV is relatively rare 
Fig. 1 — Migration of the Han population. Starting in the 5th
century, the Han population from Northern China migrated 
to Southern China and all the way to the southeast coast, 
including Hong Kong (dotted arrows). Immigration of Han 
Chinese from Southeast China to Taiwan and Singapore 
occurred from the 17th century (solid arrows).
Taiwan
Hong
Kong
Singapore
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in other parts of the world [14] and most probably in 
Northern China, although evidence of the latter is 
lacking so far.
3. HPV is the major risk factor for 
cervical carcinogenesis worldwide 
and in Chinese immigrants: HPV type-, 
variant- and load-dependent risk
Worldwide studies have disclosed extremely high risks 
of cervical cancer in women infected with different 
types of HPV, with odds ratios ranging from 62 to 
282 [22]. On the other hand, HPV transformation of 
cervical epithelium is of low efficiency and typically 
takes more than a decade to become invasive cancer. 
From worldwide epidemiology studies conducted by 
the International Agency for Research on Cancer 
(IARC), the World Health Organization (WHO) has dis-
closed other independent risk factors for cervical can-
cer, such as cigarette smoking [23], long-term use of 
oral contraceptives [24], high parity [25] and sexually 
transmitted infections (i.e., Chlamydia trachomatis
and Herpes simplex virus-2) [26,27], after adjustment 
for HPV infection. Most of these international studies, 
however, did not include the Chinese population.
Table 1 [7,18,28–31] shows the oncogenic risk of 
HPV infections in different grades of cervical neoplasia 
in Chinese subjects living in Taiwan and Hong Kong. 
Depending on the nature and stringency of selection 
of cases and controls, the odds ratio of finding squa-
mous intraepithelial lesions of high-grade (HSIL) or 
above is 29–1280 times higher in high-risk HPV (HR-
HPV)-infected women than non-infected women [7,28]. 
HPV type-specific risk for HSIL or above lesions was 
higher in women infected with HPV 16 than those in-
fected with HPV 58 and HPV 52 [29]. An earlier study 
in Taiwan also showed that HPV 52 and 58 had a much 
smaller risk for HSIL than HPV 16 [18]. Not only is it 
less risky but HPV 58-related cervical cancers also 
had a favorable survival compared to those with HPV 
16 and HPV 18 [17]. In comparison to HPV 16, 18, 31 
and 33, the E6 and E7 genes of HPV 52 had a much 
Fig. 2 — Human papillomavirus (HPV) genotype distribu-
tion in the Chinese populations of Taiwan, south China 
(Shenzang) and north China (Shenyang). The distribution 
of the three dominant HPV types (HPV 16, HPV 52, HPV 58) 
in the general population is shown.
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more limited in vitro transformation capability [32]. 
It rarely integrates into host genome in cervical can-
cer [33]. In analysis of the distributional proportion of 
different HPV types in the spectrum of cervical neo-
plasia, HPV 52 was found to be highly prevalent in pre-
cancerous infections but much less in invasive cer vical 
cancer [34], indicating a less oncogenic nature than 
other high risk types of HPV.
In addition to HPV genotypes, a study in Hong Kong 
showed that DNA sequence variations at the E7 gene 
of HPV 58 conferred different risks for cervical cancer. 
For instance, the E7 632C > T (T20I) and E7 760G > A 
(G63S) variants were associated with the severity of 
cervical neoplasia. HPV 58 variants carrying these two 
substitutions had a 6.9-fold higher risk for cervical 
cancer than variants without these substitutions [35].
With regard to HPV infection load, the amount of 
HR-HPV infection as measured by Hybrid Capture 2 
(Digene, Silver Spring, MD, USA), a higher viral load 
conferred higher risk for HSIL or above lesions [30,31]. 
Looking in more detail, the significance of HPV infec-
tion load in different severities of cervical neoplasia 
is HPV type-dependent. Two studies in Taiwan [33,36] 
showed that the viral load of HPV 16, HPV 18 and 
HPV 52 correlated significantly with disease severity. 
How ever, infection loads of HPV 58, HPV 31 and HPV 
33 do not correlate to clinical severity. The wide var-
iation in HPV infection loads among different HPV 
types and among different severities of squamous in-
traepithelial lesions makes the viral load test unreal-
istic for differentiating different severities of cervical 
neoplasia.
4. Other environmental and 
behavioral risk factors for cervical 
carcinogenesis in Chinese 
immigrants
Table 2 [8,28,30,37–41] summarizes the environ-
mental and behavioral risk factors for cervical carcino-
genesis in populations in Hong Kong, Taiwan and 
Singapore. Risk or protective factors of HPV infection 
included number of sex partners, a partner’s promis-
cuous sexual affairs, active and passive smoking, bar-
rier contraception, vitamin supplement and previous 
Pap screening, and these did not differ from those 
found in other populations. Of particular note was the 
role of frequent vaginal douching, which is a risk factor 
for prevalent HPV infection [37] as well as persistent 
low-grade squamous intraepithelial lesions. There were 
reports showing that frequent vaginal douching may 
increase a woman’s susceptibility to sexually trans-
mitted agents [42]. Vaginal douching may eliminate 
the normal vaginal microflora [43] and protective cer-
vical mucus, and increase the risk of persistence or 
acquisition of HPV by altering the vaginal milieu.
Also shown in Table 2 [8,28,30,37–41] are envi-
ronmental and behavioral factors related to risk of 
cervical cancer or cervical intraepithelial neoplasia 
(CIN), and these are similar to those found in studies 
worldwide. Universal risk factors, such as high-risk 
sexual behavior of a woman and her partner, parity 
and Chlamydia infection, were found in studies in 
Hong Kong, Taiwan and Singapore [30,38,39,41,44]. 
Of interest is the lack of cigarette smoking in the list of 
Table 1 — HPV as the oncogenic risk of cervical neoplasia in Taiwan and Hong Kong
Source Cases and controls (n) Risk target Risk factors OR (95% CI) Reference
Taiwan 40 CIN 1, 9 CIN 2, 36 HSIL+ HPV+ 122 (39–389) 7
 CIN 3, 3 ICC, 261  HR-HPV 1280 (189–8830)
 controls  MR-HPV 99 (24–411)
   LR-HPV 4.8 (0.5–48)
Taiwan 51 LSIL, 99 HSIL+, 420 LSIL HPV 52/58 12 (4–38) 18
 normal controls HSIL+ HPV 16 42 (17–105)
   HPV 52/58 29 (6–139)
   HPV 16 326 (90–1186)
Taiwan 471 LSIL, 460 HSIL+ HPV 16 8.67 (3.46–21.70) 29
 HSIL/ICC, 148 ACUS-N  HPV 52 3.04 (1.42–6.47)
 controls  HPV 58 5.22 (2.07–13.19)
Taiwan 10 LSIL, 20 HSIL, 80 HSIL HR-HPV high 6.6 (2.6–17.0) 30
 controls  viral load 18.0 (3.0–108.5)
Taiwan 19 LSIL, 32 HSIL or Lesion size High viral load Large lesion:  31
 above, 22 normal and HSIL+ (RLUs > 10) 5.3 (1.1–24.9)
    HSIL+: 35.0 (4.2–294.5)
Hong Kong 2080 population for Pap SIL Any HPV 19.51 (10.08–37.76) 28
 Smear  HR-HPV 28.91 (14.37–58.14)
   LR-HPV 1.52 (0.20–11.67)
CIN = cervical intraepithelial neoplasia; ICC = invasive cervical cancer; HSIL/LSIL = high/low grade squamous intraepithelial lesion; ASCUS-N =
colposcopy-negative ASCUS.
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risk factors in these studies. The female smoking pop-
ulation in Chinese societies is typically low [38]. A re-
cent nationwide survey of 4,160,844 Taiwanese adults 
revealed a female smoking rate of 4.5% compared 
to 42.8% in males.
5. Genetic predispositions for cervical 
carcinogenesis
Large-scale epidemiological evidence of a genetic 
pre disposition for cervical cancer has been docu-
mented [45]. DNA polymorphisms of different cancer-
related genes may confer different risks for cervical 
cancer. Table 3 [46–53] summarizes studies of risk 
for cervical neoplasia and polymorphisms, mainly in 
women in Taiwan and Hong Kong. The discovered 
polymorphic gene alleles include apoptosis-related 
genes FAS -670A/G 44, FASL -844C/CC and their as-
sociations [47], the short tandem repeat polymor-
phism of immune cytokine gene IFNG [48], tissue 
remodeling gene MMP1 -160G/GG [49], and phase I 
and II metabolizing enzymes CYP1A1 G allele and 
GSTM1-null [50]. Different human leukocyte antigen 
(HLA) gene polymorphisms and risk of HPV-related 
cervical cancer were reported in women in Hong Kong. 
Among them were HLA-A*0207/0215N or A*2402, 
which is protective for HPV 16 cervical cancer, HLA-
A*1104, which is a risk for all cervical cancer [51], 
HLA-DQ-B1*06, which is a risk for HPV 58 CIN3 and 
cervical cancer [52], HLA-DRB1*12, which is protec-
tive for CIN and cervical cancer, and HLA-DRB1*03, 
which is a risk for HPV 18 CIN and cervical cancer [53]. 
Interestingly, HLA-DQB1*03, previously found to be a 
risk allele for cervical cancer in European women, was 
found to be protective in the Hong Kong study [52].
6. New biomarkers in development: 
chromosomal loss, methylation-
silenced genes and protein markers
In additional to environmental and constitutional fac-
tors, genetic alterations affecting the growth, apopto-
sis, differentiation and genome stability of cells, and 
the angiogenesis and remodeling of tissue, are usually 
crucial steps in cancer development. They, therefore, 
serve as significant diagnostic and prognostic markers 
for cancer. They include loss of heterozygosity (LOH) or 
allelic loss, gene mutations and methylation-induced 
gene silencing.
With the dominant oncogenic effect of HPV, which 
controls cell cycle by its oncoproteins, mutations of 
tumor suppressor genes commonly found in other 
cancers were lacking in cervical cancer. Studies in 
Taiwan, Hong Kong and Singapore on P53 [54–56], 
FHIT [57], RII [58], TSG101 [59], CYCD1, CDK4 [60] 
and PTEN [61] showed absence of loss of function 
mutations. However, larger-scale chromosomal alter-
ations, such as LOH and methylation-mediated gene 
silencing, were frequently found in different grades 
of cervical carcinogenesis. Table 4 [57,62–77] sum-
marizes these genetic and epigenetic changes in cer-
vical cancers in the three areas. Allelic losses at 3p14, 
3p22-24 and 3p25 were repeatedly noted in studies 
in Taiwan [57,58,62,63] and Hong Kong [64–66]. 
Allelic losses at other chromosomal loci, such as 
5p15-5p13 [62], 1p31, 1p36.3 and 1q25 [67,68], 
were also noted in studies in Taiwan and Hong Kong. 
While the crucial genes responsible for cancer devel-
opment have yet to be identified in these chromo-
somal loci, detection of LOH and other microsatellite 
alterations in exfoliate cervical epithelial cells may 
help in the early diagnosis of cervical cancer [63].
Table 3 — Genetic polymorphisms and risk of cervical neoplasia in the Chinese population
Source Gene polymorphisms Findings Reference
Taiwan Fas-670A/A Risk for HSIL and ICC. 46
Taiwan INNG (CA)12 or (CA)14 Risk for HSIL and in accordance with severity of CIN and ICC. 48
 INNG (CA)13 or -(CA)18 Protect for HSIL and ICC in accordance with severity.
 IFNG (CA)13 Risk for HPV 58, protect for HPV18.
Taiwan MMP1 -1607G Associated with lymph node metastasis of ICC. 49
 MMP1 -1607GG Associated with advance stage of ICC.
Taiwan FAS -670A/G FAS -670A confers risk for HSIL and ICC. 47
 FAS -1377G/A -670A/G haplotype FAS -1377A/-670A haplotype and FAS -670AA/FASL -844CC
 FAS -670AA and FASL -844C/T confers a higher risk.
Taiwan CYP1A1-A/G or G/G Protect for ICC. 50
 GSTM1-null Risk for LSIL & ICC.
Hong Kong HLA-DRB1*12 Protect SIL and ICC. (The protective effect of HLA-DRB1*13 that  53
 HLA-DRB1*03 had been reported from other populations was not observed.)
  Risk for HPV-18 SIL and ICC.
Hong Kong HLA-II DQB1*03 Protect for ICC (in contrast to studies on European) risk for HPV 58  52
 HLA-II DQB1*06 CIN3 and ICC.
Hong Kong HLA-A*0207/0215N or A*2402 Protect ICC and HPV16 ICC. 51
 HLA-A*1104 Risk for ICC.
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DNA hypermethylation, with subsequent epigenetic 
silencing of tumor suppressor genes, is one of the hall-
marks of cancer and accounts for the second hit of 
the two hit hypothesis of carcinogenesis [78,79]. The 
epigenetic silencing of tumor suppressor genes is com-
monly seen in cervical cancer worldwide [80,81], as 
well as in Hong Kong, Taiwan and Singapore (Table 4). 
Among the methylated genes were P16 at 9p21 [69], 
BLU and RASSF1A at 3p21.3 [70,71], PTEN at 10q23 
[72], P73 at 1p36 [73], DAPK at 9q34, MGMT at 
10q26 [74] and DLC1 at 8p22 [75]. As noted, some 
of these methylation markers showed dramatic dif-
ferences among normal, precancerous and invasive 
carcinoma of the uterine cervix, and can be detected 
in cervical scraping samples, which potentially al-
lows self-sampling, and feature a promising diagnos-
tic biomarker compatible with and even more specific 
than the HPV test.
A number of protein biomarkers, typically defined 
by specific antibodies, have been investigated in cer-
vical cancer. Among them is p16/INK4A (p16), which 
shows promising sensitivity and specificity in the di-
agnosis of cervical high-grade dysplasia and invasive 
cancer. p16 is a tumor suppressor protein, also known 
as a cyclin-dependent kinase (CDK) inhibitor, which 
decelerates the cell cycle by inactivating CDKs. p16 
pro tein was found to be overexpressed in cervical pre-
neoplastic and neoplastic lesions in which HR-HPV ex-
isted [82,83]. Several studies in Taiwan [84–86] and 
elsewhere have demonstrated that p16 immunocyto-
chemistry can be applied successfully to conventional 
Pap smears and tissue sections, and helps to clarify 
ambiguous cytological and pathological interpretations 
such as atypical squamous cells of unknown signifi-
cance (ASCUS), atypical glands of unknown signif-
icance (AGUS) and squamous intraepithelial lesions 
[84–86]. Aside from p16, other protein markers, in-
cluding cell proliferation markers such as hTERT and 
Ki-67, were also found to be associated with HSIL and 
invasive cervical cancer [87–90]. However, these mark-
ers also appeared in pro liferative and reactive cells, and 
thus limited their specificity and future applications.
Table 4 — Chromosome allelic losses and methylation of tumor suppressor genes in cervical neoplasia in Taiwan, 
Hong Kong and Singapore
Loss of heterozygosity of chromosomal loci
Source Chromosome loci Findings Reference
Taiwan 5p15.1-15.3 Genomic deletion on 3p and 5p correlated with genetic or epigenetic p53  62
  inactivation pathways, including p53 mutation, genetic deletion of p53 and
  cervical infection with HPV.
Hong Kong 3p14, 3p25, 9 loci  LOH was found in 10/12 ICC at 3p25 and 10/11 cases at 3p14. 64–66
 at 3p The incidence of LOH at 3p13 was the highest among 9 markers examined.
  Frequent LOH was found at 3p26 (41%), 3p25 (31%), 3p25.1 (24%), 3p21
  (29%), 3p1 (24%), and 3p13 (25%) in CIN.
Taiwan 3p14, 3p22-24,  37% ICC showed LOH at 3p14 and 43% showed LOH at 3p22-24. 57,62,63,
 3p25 LOH at one of the three sites was observed in 23%, 27% and 31% of LSILs, 76
  HSILs, and ICC.
Hong Kong 1p31, 1p36.3,  LOH at 1p31, 1p36.3 and 1q25 exceeded 30%. 67,68
 1q25 12 other loci exhibited frequencies of LOH of 20–30%.
Methylation silencing of tumor suppressor genes
Source Gene Findings
Hong Kong RASSFIA at 3p21 8/12 hypermethylated primary cancers showed concomitant LOH at 3p21. 70
Taiwan BLU &  BLU was methylated in 76.9% of ICC, 57.4% of HSIL, 20.0% of LSIL and  71
 RASSF1A at 12.5% of normal tissues (p < 0.001).
 3p21.3 RASSF1A was methylated in 15% of ICC, 17.5% of HSIL, but not in LSIL
  or normal.
  The methylation of RASSF1A was inversely related to HPV infection in
  patients with HSIL/SCC (p = 0.003).
Hong Kong PTEN at 10q23 PTEN was methylated in 40% HSIL and 58% ICC. 72
Hong Kong P73 at 1p36 P73 was methylated in 39% ICC, conferring resistance to radiotherapy. 73
Hong Kong DAPK at 9q34,  Methylation rate of DAPK, P16 and MGMT in ICC were 60%, 28.2% and 74
 p16 at 9p21, and 18.8%, respectively.
 MGMT at 10q26
Hong Kong p16/INK4A at   p16/INK4A was methylated in 31% of ICC. 69
 9p21
Singapore DLC1 at 8p22 DLC1 was methylated and silenced in 7/8 CxCa. 75
Singapore HPV 16 LCR HPV 16 LCR was methylated in 52% of subclinical HPV, 21.7% of  77
  precursor lesions and 6.1% of ICC.
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7. Perspectives
In this post-genomic era when the code, control and 
function of the human genome is being quickly un-
veiled, characteristic genotypic and phenotypic changes 
in human cancers are being discovered at an ever in-
creasing pace. With the aid of various genome-wide 
technologies, genetic and epigenetic markers for can-
cers are emerging systemically and in an overwhelm-
ing way. With the massive candidate markers being 
discovered, each has to be verified and tested clini-
cally in line with the risk, diagnosis and prognosis of 
cancer. In a disease that is caused by persistent viral 
infection, and whose fate is determined by long-term 
host-viral and host-environmental interactions, it is 
not surprising to see a common spectrum of type- or 
variant-specific HPV prevalence, with similar behav-
ioral and environmental risk factors for cervical cancer 
in people in Taiwan, Hong Kong and Singapore, who 
share a great similarity in genetic background, culture 
and social systems. With the emergence of more and 
more candidate tumor markers, and the rate-limiting 
nature of translational research, further investigation 
into this fascinating disease will demand systematic 
work among these and other regions in a collaborative, 
as well as competitive, way.
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